Metformin research highlights skin cancer benefits and geriatric risks

Research regarding the diabetes medication metformin highlights both potential therapeutic benefits and specific risks for certain populations.

A study led by Dr. Tiffany Libby of Brown University, utilizing data from the U.S. National Institutes of Health, suggests that metformin use may be associated with a significantly lower risk of developing the two most common types of non-melanoma skin cancer: basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). The analysis compared thousands of individuals and found the relationship persisted even after adjusting for other variables.

Conversely, medical experts advise caution when prescribing metformin to elderly patients. Due to age-related declines in renal function, the drug can accumulate in the body, increasing the risk of lactic acidosis, a rare but potentially fatal complication. The physiological changes in older adults, including increased comorbidities and polypharmacy, necessitate a highly individualized approach to treatment.